RPA34 Antibody

What is RPA34 and why are antibodies against it important in research?

RPA34 is a nuclear protein belonging to the Eukaryotic RPA34 RNA polymerase subunit protein family. It's widely expressed across various tissue types and undergoes phosphorylation as a post-translational modification . RPA34 antibodies are critical research tools for detecting the protein's expression, localization, and modification status, particularly in DNA damage response studies where RPA34 phosphorylation serves as an important marker for pathway activation .

What are the common synonyms and related proteins for RPA34?

Researchers should be aware of several alternative names used in the literature:

• RNA polymerase I subunit G (POLR1G)

• ASE-1/ASE1

• CAST

• RPA2 (used interchangeably in some contexts)

• CD3EAP (related protein)

Understanding these alternative designations is essential when searching literature or selecting appropriate antibodies for experiments.

What applications are RPA34 antibodies validated for?

RPA34 antibodies have been validated for multiple research applications:

Western blotting is the most commonly used and reliable application, particularly for studying RPA34's role in DNA damage response pathways .

How should researchers design controls when using RPA34 antibodies?

Proper experimental design requires several controls:

• Positive controls: Use cell lines known to express RPA34 (widely expressed in many tissues)

• Negative controls:

  • Primary antibody omission

  • Isotype-matched control antibody

  • RPA34 knockdown samples (siRNA or CRISPR)

• Treatment validation:

  • Untreated versus DNA damage-induced samples

  • Phosphatase treatment when studying phosphorylated forms

• Specificity verification:

  • Blocked peptide competition assays

  • Multiple antibodies targeting different RPA34 epitopes

These controls ensure signal specificity and experimental validity when working with RPA34 antibodies.

What are optimal conditions for detecting RPA34 phosphorylation after DNA damage?

For reliable detection of RPA34 phosphorylation following DNA damage:

• Timing: Harvest cells at multiple timepoints (typically 0.5-4 hours post-treatment)

• Damage induction: UV irradiation effectively induces RPA34 phosphorylation

• Sample preparation:

  • Include phosphatase inhibitors in all buffers

  • Consider subcellular fractionation to enrich for chromatin-bound proteins

  • Use lower percentage SDS-PAGE gels (6-8%) for better resolution of phosphorylation-induced band shifts

• Detection strategies:

  • Use phospho-specific antibodies targeting Ser4/Ser8 residues

  • Look for both specific phospho-signal and characteristic band shift in total RPA34

These methodological details are critical for reproducible detection of RPA34 phosphorylation events.

How can researchers distinguish between phosphorylated and non-phosphorylated forms of RPA34?

Distinguishing between phosphorylated and non-phosphorylated forms requires:

• Antibody selection:

  • Phospho-specific antibodies that recognize RPA34 only when phosphorylated at Ser4/Ser8

  • Total RPA34 antibodies that detect all forms

• Electrophoretic analysis:

  • Phosphorylated RPA34 shows a characteristic mobility shift (higher apparent molecular weight) when detected with total RPA34 antibodies

  • This band shift provides confirmatory evidence alongside phospho-specific antibody signals

• Validation approaches:

  • Parallel samples treated with phosphatase to remove phosphorylation

  • ATR kinase inhibition to prevent RPA34 phosphorylation

These approaches provide complementary evidence for RPA34 phosphorylation status.

What is the relationship between BRIT1 and RPA34 in DNA damage response?

Research has established that:

• BRIT1 functions upstream of RPA34 in the DNA damage response pathway

• BRIT1 depletion significantly decreases UV-induced binding of RPA subunits (including RPA34) to chromatin

• BRIT1 is required for the UV-induced phosphorylation of RPA34 at Ser4/Ser8 residues

• Without BRIT1, proper recruitment of RPA34 to damaged DNA sites fails to occur

This relationship highlights the importance of BRIT1 as a regulator of early DNA damage response processes involving RPA34 and its phosphorylation.

How does RPA34 phosphorylation integrate into broader DNA damage signaling?

RPA34 phosphorylation represents a crucial node in DNA damage signaling:

• Following UV damage, ATR kinase phosphorylates RPA34 at Ser4/Ser8 residues

• This phosphorylation depends on proper recruitment of RPA34 to chromatin, which requires BRIT1

• Phosphorylated RPA34 serves as both a damage marker and a functional component in the damage response

• The phosphorylation status of RPA34 can be monitored as a readout of ATR pathway activation

• This modification links the initial damage sensing to downstream checkpoint activation and repair processes

Understanding this integration allows researchers to contextualize RPA34 within the broader cellular response to genomic insults.

How can researchers use RPA34 antibodies to monitor DNA repair pathway choice?

RPA34 antibodies can provide insights into repair pathway dynamics:

• Pathway-specific responses:

  • Different DNA damaging agents produce distinctive patterns of RPA34 phosphorylation

  • UV damage strongly induces RPA34 phosphorylation through the ATR pathway

• Temporal dynamics:

  • Time-course analysis using RPA34 antibodies can reveal the kinetics of pathway activation

  • Both phospho-specific and total RPA34 antibodies should be used to track modifications over time

• Co-localization studies:

  • Immunofluorescence with RPA34 antibodies alongside markers for specific repair pathways

  • Analysis of RPA34 co-localization with BRIT1, 53BP1, or other factors reveals pathway engagement

• Genetic approaches:

  • In cells with specific repair deficiencies, RPA34 phosphorylation patterns may be altered

  • These changes can be detected using appropriate RPA34 antibodies

These applications allow researchers to determine how cells channel DNA damage into specific repair pathways.

What are common issues when detecting RPA34 by Western blot?

Researchers frequently encounter these challenges:

When specifically analyzing phosphorylated RPA34, remember that total RPA34 antibodies will show a band shift, while phospho-specific antibodies will detect only the modified form .

How can researchers differentiate between RPA34 and related proteins?

Distinguishing RPA34 from related proteins requires:

• Careful antibody selection:

  • Choose antibodies validated for specificity against RPA34 versus related proteins

  • Consider epitope location when selecting antibodies

• Molecular weight verification:

  • RPA34 appears at approximately 34 kDa on Western blots

  • Related proteins like RPA70 have distinctly different molecular weights

• Validation strategies:

  • RPA34-specific siRNA knockdown to confirm antibody specificity

  • Expression of tagged RPA34 for positive identification

  • Mass spectrometry to confirm protein identity in complex samples

• Localization patterns:

  • RPA34 is primarily nuclear , which can help distinguish it from cytoplasmic proteins

These approaches ensure that observed signals are specific to RPA34 rather than related proteins.

What factors affect the choice of RPA34 antibodies for specific applications?

When selecting RPA34 antibodies, consider:

• Target species compatibility:

  • Ensure the antibody recognizes RPA34 in your experimental species (human, mouse, etc.)

• Application validation:

  • Verify the antibody has been validated for your specific technique (WB, IHC, IF)

• Epitope considerations:

  • For phosphorylation studies: antibodies targeting Ser4/Ser8 residues

  • For total protein detection: antibodies recognizing conserved regions

  • For protein interaction studies: avoid antibodies targeting interaction domains

• Antibody characteristics:

  • Monoclonal: greater specificity but potentially less sensitive

  • Polyclonal: higher sensitivity but potentially more background

  • Host species: compatibility with other antibodies for co-staining

• Available validation data:

  • Published literature citing the antibody

  • Manufacturer validation in relevant applications

These considerations ensure selection of the most appropriate antibody for specific experimental needs.

How can RPA34 antibodies facilitate studies of cancer therapy mechanisms?

RPA34 antibodies enable several advanced cancer research applications:

• Therapy response biomarkers:

  • Monitor RPA34 phosphorylation as a readout of DNA damage response activation

  • Track pathway activation in response to chemotherapeutics or radiotherapy

• Resistance mechanism studies:

  • Compare RPA34 phosphorylation patterns between sensitive and resistant cancer cells

  • Evaluate how alterations in the BRIT1-RPA34 axis affect therapy response

• Combination therapy development:

  • Use RPA34 phosphorylation as a marker for evaluating synergistic effects when combining treatments

  • Test how pathway inhibitors affect RPA34 phosphorylation and cancer cell survival

• Patient-derived samples:

  • Apply RPA34 antibodies in immunohistochemistry to assess pathway activation in clinical specimens

  • Correlate RPA34 phosphorylation patterns with treatment outcomes

These applications contribute to understanding therapy mechanisms and potential biomarker development.

How can researchers investigate novel functions of RPA34 beyond DNA damage response?

To explore novel RPA34 functions:

• Chromatin immunoprecipitation (ChIP):

  • Use RPA34 antibodies for ChIP-seq to map genomic binding sites

  • Analyze whether RPA34 associates with specific gene regulatory regions

• RNA-protein interactions:

  • RNA immunoprecipitation with RPA34 antibodies to identify potential RNA targets

  • Investigate potential roles in RNA metabolism beyond transcription

• Protein complex analysis:

  • Immunoprecipitation with RPA34 antibodies followed by mass spectrometry

  • Identify novel protein interaction partners under various cellular conditions

• Cellular stress responses:

  • Monitor RPA34 modifications in response to diverse stressors (oxidative stress, hypoxia)

  • Determine if RPA34 integrates multiple stress response pathways

• Cell-specific functions:

  • Compare RPA34 expression, localization, and modification across different cell types and tissues

These approaches can reveal unexpected RPA34 functions beyond its established roles.

What experimental approaches combine RPA34 antibodies with emerging technologies?

Integrating RPA34 antibodies with cutting-edge methods enables novel insights:

• Proximity labeling:

  • Couple RPA34 antibodies with BioID or APEX2 systems to identify proteins in close proximity

  • Map the dynamic RPA34 interactome during DNA damage response

• Super-resolution microscopy:

  • Use fluorescently-labeled RPA34 antibodies for nanoscale localization studies

  • Visualize RPA34 recruitment to damage sites with unprecedented resolution

• Single-cell analysis:

  • Apply RPA34 antibodies in single-cell Western blot or CyTOF

  • Characterize cell-to-cell heterogeneity in RPA34 expression and phosphorylation

• CRISPR screens:

  • Use RPA34 antibodies as readouts in functional genomic screens

  • Identify novel regulators of RPA34 function or phosphorylation

• Organoid models:

  • Apply RPA34 antibodies to study DNA damage response in 3D tissue models

  • Compare RPA34 dynamics in physiologically relevant systems

These integrated approaches represent the frontier of RPA34 research, combining antibody-based detection with state-of-the-art technologies.